XTLB
NASD XTL Biopharmaceuticals Ltd. Sponsored ADR$1.92 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.92, $0.03 below the day’s high of $1.95
- YTD change
- -17.24%
- vs 20-day SMA
- -14.98%
- vs 200-day SMA
- -31.30%
Price ranges
Price & Performance
-0.48 (-19.83%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 96.1% away from all-time highs of $49.42
- XTLB is down 17% since the beginning of the year
- XTLB is down 66% over the past 12 months
- XTLB is down 24% over the past 1 month
- 0% of all XTLB investors are betting against XTLB
XTLB reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +41.2%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -11.11%
- vs 8-day SMA
- -8.24%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.